Use of niacin as a drug.

INTRODUCTION ...... 169 NIACIN AS A NUTRIENT....... ....... ...... . .... .... 171 NIACIN AS A DRUG ........ ... . .. ........ 172 Biotransformation Patterns 172 Pharmacologic Actions of Nicotinic Acid . . . ....... . ... . ..... . . .... 173 Pharmacologic Actions of Nicotinamide 179 Structure-Activity Relationships 180 Pharmacokinetics ... ..... ..... 181 Toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182 Miscellaneous Uses ........ . ..... ......... 182 SUMMARY AND PROSPECTS FOR FUTURE STUDIES ..... 182

[1]  N. Kaplan,et al.  Lactate dehydrogenases: structure and function. , 2006, Advances in enzymology and related areas of molecular biology.

[2]  Y. Giudicelli,et al.  Increased sensitivity of fat cell adenylate cyclase to stimulatory agonists during fasting is not related to impaired inhibitory coupling system , 1986, FEBS letters.

[3]  H. Brewer,et al.  Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. , 1985, Atherosclerosis.

[4]  A. Hamsten,et al.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid , 1989, Journal of internal medicine.

[5]  G. Mullin,et al.  Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. , 1989, Annals of internal medicine.

[6]  H. L. Mason,et al.  Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. , 1961, JAMA.

[7]  J. Albers,et al.  Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. , 1985, Metabolism: clinical and experimental.

[8]  T. Hamazaki,et al.  The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid. , 1985, Atherosclerosis.

[9]  A. Roscher,et al.  Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. , 1983, The Journal of clinical investigation.

[10]  G. Rosenhamer,et al.  Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. , 1977, Atherosclerosis.

[11]  P. Casey,et al.  Role of G proteins in transmembrane signaling. , 1988, Cold Spring Harbor symposia on quantitative biology.

[12]  C. Blum,et al.  High density lipoprotein metabolism in man. , 1977, The Journal of clinical investigation.

[13]  I. Walker,et al.  Synthetic fibrinolytic agents. , 1979, Progress in cardiovascular diseases.

[14]  W. Hotz.  Nicotinic acid and its derivatives: a short survey. , 1983, Advances in lipid research.

[15]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[16]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[17]  W. J. Turner,et al.  Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. , 1976, Clinical chemistry.

[18]  K. Johnson,et al.  Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. , 1990, JAMA.

[19]  C. Packard,et al.  Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. , 1979, The Journal of clinical investigation.

[20]  H. Okamoto,et al.  Amelioration of Diabetes Mellitus in Partially Depancreatized Rats by Poly(ADP-ribose) Synthetase Inhibitors: Evidence of Islet B-Cell Regeneration , 1984, Diabetes.

[21]  A. Hoffer,et al.  Influence of nicotinic acid on serum cholesterol in man. , 1955, Archives of biochemistry and biophysics.

[22]  L. Carlson,et al.  Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. , 2009, Acta medica Scandinavica.

[23]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[24]  S. Moncada,et al.  Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. , 1988, Biochemical pharmacology.

[25]  Kiff Rs,et al.  Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. , 1988 .

[26]  F. Sacks,et al.  Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. , 1989, The American journal of cardiology.

[27]  M. Mihatsch,et al.  Factors associated with early remission of type I diabetes in children treated with cyclosporine. , 1988, The New England journal of medicine.

[28]  L. Benet,et al.  Pharmacokinetics of nicotinic acid – salicylic acid interaction , 1989, Clinical pharmacology and therapeutics.

[29]  R. Andersson,et al.  Studies on the mechanism of flush induced by nicotinic acid. , 2009, Acta pharmacologica et toxicologica.

[30]  R. Krauss,et al.  Regulation of high density lipoprotein levels. , 1982, The Medical clinics of North America.

[31]  A. Heggelund,et al.  Influence of indomethacin on flush induced by nicotinic acid in man. , 2009, Acta pharmacologica et toxicologica.

[32]  O. Brown,et al.  Niacin Reduces Paraquat Toxicity in Rats. , 1981, Science.

[33]  S. Rössner,et al.  Coronary Drug Project Research Group. , 1978, Atherosclerosis.

[34]  G. Walldius,et al.  Effects of nicotinic acid on concentrations of serum apolipoproteins B, C-I, C-II, C-III and E in hyperlipidemic patients. , 2009, Acta medica Scandinavica.

[35]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[36]  P. Arner,et al.  Inhibition of Lipolysis by Agents Acting Via Adenylate Cyclase in Fat Cells from Infants and Adults , 1989, Pediatric Research.